Virological response to initial antiretroviral regimens containing abacavir or tenofovir

UK Collaborative HIV Cohort Study; Loveleen Bansi; Caroline Sabin; Richard Gilson; Brian Gazzard; Clifford Leen; Jane Anderson; David Dunn; Teresa Hill; Martin Fisher; Jonathan Ainsworth; Deenan Pillay; Margaret Johnson; John Walsh; Chloe Orkin; Philippa Easterbrook; Mark Gompels; Andrew Phillips

doi:10.1086/605024

Virological response to initial antiretroviral regimens containing abacavir or tenofovir

UK Collaborative HIV Cohort Study, Loveleen Bansi, Caroline Sabin, Richard Gilson, Brian Gazzard, Clifford Leen, Jane Anderson, David Dunn, Teresa Hill, Martin Fisher, Jonathan Ainsworth, Deenan Pillay, Margaret Johnson, John Walsh, Chloe Orkin, Philippa Easterbrook, Mark Gompels, Andrew Phillips

College of Medicine and Veterinary Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Patients with a baseline viral load >100,000 copies/mL receiving abacavir (ABC) as part of the nucleoside-backbone component of their first highly active antiretroviral therapy (HAART) regimen have been reported to have a greater failure rate than those receiving tenofovir (TDF). We analyzed short-term outcomes of the use of HAART combinations that included ABC or TDF. The mean 2-8-week change in viral load was calculated using linear regression. In total, 1136 patients started ABC, and 412 started TDF. After adjustment for baseline viral load and other factors, there was no difference in the change in viral load between the patients who started ABC and those who started TDF (0.03 [95% confidence interval, -0.07 to 0.12]) log copies/mL; P = .59). Furthermore, there was no evidence that this effect differed according to baseline viral load (P = .88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART.

Original language	English
Pages (from-to)	710-4
Number of pages	5
Journal	The Journal of Infectious Diseases
Volume	200
Issue number	5
DOIs	https://doi.org/10.1086/605024
Publication status	Published - 1 Sep 2009

Keywords

Adenine
Anti-HIV Agents
Antiretroviral Therapy, Highly Active
Dideoxynucleosides
Female
HIV Infections
HIV-1
Humans
Male
Organophosphonates
Treatment Failure
Treatment Outcome
Viral Load

Access to Document

10.1086/605024

Cite this

UK Collaborative HIV Cohort Study, Bansi, L., Sabin, C., Gilson, R., Gazzard, B., Leen, C., Anderson, J., Dunn, D., Hill, T., Fisher, M., Ainsworth, J., Pillay, D., Johnson, M., Walsh, J., Orkin, C., Easterbrook, P., Gompels, M., & Phillips, A. (2009). Virological response to initial antiretroviral regimens containing abacavir or tenofovir. The Journal of Infectious Diseases, 200(5), 710-4. https://doi.org/10.1086/605024

@article{c06409941c6745bf91efa55752b676da,

title = "Virological response to initial antiretroviral regimens containing abacavir or tenofovir",

abstract = "Patients with a baseline viral load >100,000 copies/mL receiving abacavir (ABC) as part of the nucleoside-backbone component of their first highly active antiretroviral therapy (HAART) regimen have been reported to have a greater failure rate than those receiving tenofovir (TDF). We analyzed short-term outcomes of the use of HAART combinations that included ABC or TDF. The mean 2-8-week change in viral load was calculated using linear regression. In total, 1136 patients started ABC, and 412 started TDF. After adjustment for baseline viral load and other factors, there was no difference in the change in viral load between the patients who started ABC and those who started TDF (0.03 [95% confidence interval, -0.07 to 0.12]) log copies/mL; P = .59). Furthermore, there was no evidence that this effect differed according to baseline viral load (P = .88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART.",

keywords = "Adenine, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Dideoxynucleosides, Female, HIV Infections, HIV-1, Humans, Male, Organophosphonates, Treatment Failure, Treatment Outcome, Viral Load",

author = "{UK Collaborative HIV Cohort Study} and Loveleen Bansi and Caroline Sabin and Richard Gilson and Brian Gazzard and Clifford Leen and Jane Anderson and David Dunn and Teresa Hill and Martin Fisher and Jonathan Ainsworth and Deenan Pillay and Margaret Johnson and John Walsh and Chloe Orkin and Philippa Easterbrook and Mark Gompels and Andrew Phillips",

year = "2009",

month = sep,

day = "1",

doi = "10.1086/605024",

language = "English",

volume = "200",

pages = "710--4",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

UK Collaborative HIV Cohort Study, Bansi, L, Sabin, C, Gilson, R, Gazzard, B, Leen, C, Anderson, J, Dunn, D, Hill, T, Fisher, M, Ainsworth, J, Pillay, D, Johnson, M, Walsh, J, Orkin, C, Easterbrook, P, Gompels, M & Phillips, A 2009, 'Virological response to initial antiretroviral regimens containing abacavir or tenofovir', The Journal of Infectious Diseases, vol. 200, no. 5, pp. 710-4. https://doi.org/10.1086/605024

TY - JOUR

T1 - Virological response to initial antiretroviral regimens containing abacavir or tenofovir

AU - UK Collaborative HIV Cohort Study

AU - Bansi, Loveleen

AU - Sabin, Caroline

AU - Gilson, Richard

AU - Gazzard, Brian

AU - Leen, Clifford

AU - Anderson, Jane

AU - Dunn, David

AU - Hill, Teresa

AU - Fisher, Martin

AU - Ainsworth, Jonathan

AU - Pillay, Deenan

AU - Johnson, Margaret

AU - Walsh, John

AU - Orkin, Chloe

AU - Easterbrook, Philippa

AU - Gompels, Mark

AU - Phillips, Andrew

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Patients with a baseline viral load >100,000 copies/mL receiving abacavir (ABC) as part of the nucleoside-backbone component of their first highly active antiretroviral therapy (HAART) regimen have been reported to have a greater failure rate than those receiving tenofovir (TDF). We analyzed short-term outcomes of the use of HAART combinations that included ABC or TDF. The mean 2-8-week change in viral load was calculated using linear regression. In total, 1136 patients started ABC, and 412 started TDF. After adjustment for baseline viral load and other factors, there was no difference in the change in viral load between the patients who started ABC and those who started TDF (0.03 [95% confidence interval, -0.07 to 0.12]) log copies/mL; P = .59). Furthermore, there was no evidence that this effect differed according to baseline viral load (P = .88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART.

AB - Patients with a baseline viral load >100,000 copies/mL receiving abacavir (ABC) as part of the nucleoside-backbone component of their first highly active antiretroviral therapy (HAART) regimen have been reported to have a greater failure rate than those receiving tenofovir (TDF). We analyzed short-term outcomes of the use of HAART combinations that included ABC or TDF. The mean 2-8-week change in viral load was calculated using linear regression. In total, 1136 patients started ABC, and 412 started TDF. After adjustment for baseline viral load and other factors, there was no difference in the change in viral load between the patients who started ABC and those who started TDF (0.03 [95% confidence interval, -0.07 to 0.12]) log copies/mL; P = .59). Furthermore, there was no evidence that this effect differed according to baseline viral load (P = .88 for the interaction between pre-HAART viral load and nucleoside started). Likewise, there was no difference in rates of virological failure between the 2 drugs at 24-48 weeks after starting HAART.

KW - Adenine

KW - Anti-HIV Agents

KW - Antiretroviral Therapy, Highly Active

KW - Dideoxynucleosides

KW - Female

KW - HIV Infections

KW - HIV-1

KW - Humans

KW - Male

KW - Organophosphonates

KW - Treatment Failure

KW - Treatment Outcome

KW - Viral Load

U2 - 10.1086/605024

DO - 10.1086/605024

M3 - Article

C2 - 19635022

VL - 200

SP - 710

EP - 714

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -

Virological response to initial antiretroviral regimens containing abacavir or tenofovir

Abstract

Keywords

Access to Document

Fingerprint

Cite this